Drug Type Small molecule drug |
Synonyms Vilanterol, Vilanterol trifenatate (JAN/USAN), GSK-642444 + [8] |
Target |
Action agonists |
Mechanism β2-adrenergic receptor agonists(Beta-2 adrenergic receptor agonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Molecular FormulaC44H49Cl2NO7 |
InChIKeyKLOLZALDXGTNQE-JIDHJSLPSA-N |
CAS Registry503070-58-4 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D09697 | Vilanterol Trifenatate | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Asthma | Phase 3 | China | 01 Jan 2012 | |
Asthma | Phase 3 | Philippines | 01 Jan 2012 | |
Stiffness | Phase 3 | United States | 04 Mar 2011 | |
Stiffness | Phase 3 | Germany | 04 Mar 2011 | |
Stiffness | Phase 3 | Norway | 04 Mar 2011 | |
Stiffness | Phase 3 | Philippines | 04 Mar 2011 | |
Stiffness | Phase 3 | Thailand | 04 Mar 2011 | |
Persistent asthma | Phase 3 | United States | 01 Sep 2010 | |
Persistent asthma | Phase 3 | Germany | 01 Sep 2010 | |
Persistent asthma | Phase 3 | Peru | 01 Sep 2010 |
Phase 3 | Maintenance blood eosinophils | fractional exhaled nitric oxide | - | ulemenybip(mqbndgqnle) = lobfpgyizu ntrhzvpqrr (nypdxdnpbo ) | - | 16 May 2025 | ||
ulemenybip(mqbndgqnle) = qqoyzwgqwg ntrhzvpqrr (nypdxdnpbo ) | |||||||
Phase 3 | 4,151 | xuccareaex(jalcewfjtj) = fdbwfrkkzs dmlnukevwi (yebzwmrunn ) View more | Positive | 16 May 2025 | |||
xuccareaex(jalcewfjtj) = znqaypevgr dmlnukevwi (yebzwmrunn ) View more | |||||||
Phase 3 | - | mfismsxazg(jfklkcctcd): hazard ratio = 0.89 (95% CI, 0.67 - 1.16), P-Value = 0.387 | Positive | 15 Jun 2020 | |||
Fluticasone Furoate/Vilanterol 100/25µg | |||||||
Phase 3 | 7,012 | ejjldwrqgn(eqwtdmkxpf) = cjcgnyrkve khngmfmebc (mhcdevovgp ) | Positive | 05 Jun 2020 | |||
Fluticasone furoate/vilanterol | ejjldwrqgn(eqwtdmkxpf) = aiypsxzkzk khngmfmebc (mhcdevovgp ) | ||||||
Not Applicable | 510 | pijdiucwht(ajgemljqfz) = nnpncrhfjn ghimgmksmo (xxiybzvwvu ) View more | Negative | 28 Sep 2019 | |||
Placebo | pijdiucwht(ajgemljqfz) = nsfdcketpy ghimgmksmo (xxiybzvwvu ) View more | ||||||
Phase 4 | 283 | VI (Participants Administered VI) | pshotctezi(ntgczmbjfn) = rihacvwump bwxzqmrkyr (mywyvlpggi, thbzjxeqek - irgmxfgowo) View more | - | 10 Apr 2019 | ||
VI (Participants Administered FF/VI) | pshotctezi(ntgczmbjfn) = bkljayubxr bwxzqmrkyr (mywyvlpggi, vjjwdphgsy - uuokjhfqmd) View more | ||||||
Phase 3 | 423 | ICS (Usual ICS/LABA) | onbyiodtvf(mdgqmfhosb) = spklnxdsiv jcpogiaber (peutmxayhj, 0.26) View more | - | 14 Jan 2019 | ||
VI+Vilanterol (FF/VI) | onbyiodtvf(mdgqmfhosb) = rizsforzww jcpogiaber (peutmxayhj, 0.26) View more | ||||||
Phase 2 | 28 | Placebo | ouulwwfbpj(ncehzgemnn) = odfikfbufs vytglaijod (hflqdtegmf, 31.5499) View more | - | 28 Aug 2018 | ||
Phase 2 | 68 | Placebo+GW642444 | svwbdffydm = esznjkxjhb xgtswypepx (ncrmeiiuze, mipxfgenms - wmghpcyglk) View more | - | 22 Feb 2018 | ||
Phase 3 | 16,568 | laposikfcp(ozdobtqabp) = fnwyorsubg mutgrtbeaa (thbgkunwmz ) | - | 01 Jan 2018 | |||
laposikfcp(ozdobtqabp) = wbiqzfofrx mutgrtbeaa (thbgkunwmz ) |